K. Baker
7 Papers
K. Baker is an academic researcher. The author has contributed to research in topics: Internal medicine & Azacitidine. The author has an hindex of 2, co-authored 6 publications.
Chat about Author
Papers
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
Stéphane de Botton,Thomas Cluzeau,Carlos E. Vigil,Rachel J. Cook,Philippe Rousselot,David A. Rizzieri,Jane L. Liesveld,Pierre Fenaux,Thorsten Braun,Anne Banos,Joseph G. Jurcic,Mikkael A. Sekeres,Michael R. Savona,Gail J. Roboz,Dale L. Bixby,Kate Madigan,Angela Volkert,Kristin Stephens,Qing Kang-Fortner,K. Baker,Sofia Paul,Michael R. McKeown,John P. Carulli,Matthew L. Eaton,Graeme Hodgson,Christopher Fiore,Michael Kelly,David A. Roth,Eytan M. Stein +28 more
TL;DR: In this paper , Tamibarotene plus azacitidine was associated with a high CR rate and a rapid onset of response in RARA-positive newly diagnosed unfit AML.
21
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
Eytan M. Stein,Stéphane de Botton,Thomas Cluzeau,Arnaud Pigneux,Jane L. Liesveld,Rachel J. Cook,Philippe Rousselot,David A. Rizzieri,Thorsten Braun,Gail J. Roboz,Delphine Lebon,Maël Heiblig,K. Baker,Angela Volkert,Sofia Paul,Nisha Rajagopal,David A. Roth,Michael Kelly,Pierre Peterlin +18 more
TL;DR: The favorable safety profile and preliminary clinical activity support the development of combination therapies with tamibarotene in myeloid malignancies with RARA overexpression.
4
A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1).
Amy E. DeZern,Giovanni Marconi,Dries Deeren,Maria Diez Campelo,Michael Lübbert,M. Krishnamurthy,Zsolt Nagy,Grzegorz W. Basak,Elena V. Morozova,Klaus Geissler,Yishai Ofran,Heather Kelley,Angela Volkert,K. Baker,Qing Kang-Fortner,Catherine Madigan,David M. Roth,Michael Kelly,Pierre Fenaux +18 more
TL;DR: This Phase 3, multi-center, randomized, double-blind, placebo-controlled study will compare activity of tamibarotene/aza to placebo/aza in RARA+ patients with ND HR-MDS to improve clinical outcomes of standard of care treatment with hypomethylating agents (HMAs).
3
MDS-110 SELECT-MDS-1 Trial in Progress: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tamibarotene/Azacitidine Versus Placebo/Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk MDS.
Amy E. DeZern,Pierre Fenaux,Dries Deeren,María Díez-Campelo,Michael Lübbert,M. Krishnamurthy,Zsolt Nagy,Grzegorz W. Basak,Anna Jonáš ová,Klaus Geissler,Yishai Ofran,Angela Volkert,K. Baker,Jaime Chisholm,Qing Kang-Fortner,David A. Roth,Michael Kelly,Giovanni Marconi +17 more
TL;DR: A novel genomically defined subset of higher-risk myelodysplastic syndrome (HR-MDS) patients with an actionable target characterized by overexpression of RARA has been identified by a blood-based biomarker test as discussed by the authors .
Pb1921: a randomized, double-blind, phase 3 study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for rara-positive hr-mds (select-mds-1)
Amy E. DeZern,G. Marconi,Dries Deeren,Maria Diez Campelo,Michael Lübbert,P. Krishnamurthy,Zsófia Flóra Nagy,Gourab Basak,Anna Jonasova,Ekaterina Morozova,Katrin Geissler,Yishai Ofran,Heather Kelley,Angela Volkert,K. Baker,Qing Kang-Fortner,Gabrielle Hodgson,Catherine Madigan,David A. Roth,Michael Kelly,Pierre Fenaux +20 more
TL;DR: A novel genomically defined subset of higher-risk MDS patients with an actionable target characterized by overexpression of RARA has been identified and this RARA positivity enables biologically targeted therapy with tamibarotene.